Holen Sie sich die Stockscreener-App
2.57
0.78%
0.02
Handel nachbörslich:
2.56
-0.010
-0.39%
Schlusskurs vom Vortag:
$2.55
Offen:
$2.55
24-Stunden-Volumen:
249.63K
Relative Volume:
0.58
Marktkapitalisierung:
$129.73M
Einnahmen:
$17.63M
Nettoeinkommen (Verlust:
$-57.71M
KGV:
-1.7365
EPS:
-1.48
Netto-Cashflow:
$-60.45M
1W Leistung:
+27.54%
1M Leistung:
-14.33%
6M Leistung:
-41.46%
1J Leistung:
-41.86%
1-Tages-Spanne:
$2.50
$2.5891
1-Wochen-Bereich:
$2.00
$2.71
52-Wochen-Spanne:
$1.94
$5.65
Scpharmaceuticals Inc Stock (SCPH) Company Profile
Firmenname
Scpharmaceuticals Inc
Sektor
Branche
Telefon
617-517-0730
Adresse
25 BURLINGTON MALL ROAD, SUITE 203, BURLINGTON, MA
Vergleichen Sie SCPH mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SCPH
Scpharmaceuticals Inc
|
2.57 | 129.73M | 17.63M | -57.71M | -60.45M | -1.48 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.10 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.16 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.20 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.56 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Scpharmaceuticals Inc Stock (SCPH) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-09-07 | Eingeleitet | Craig Hallum | Buy |
| 2022-12-01 | Eingeleitet | Cowen | Outperform |
| 2022-10-21 | Fortgesetzt | Jefferies | Buy |
| 2022-10-11 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2022-08-02 | Eingeleitet | Maxim Group | Buy |
| 2021-09-09 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2019-10-15 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-01-30 | Herabstufung | Leerink Partners | Outperform → Mkt Perform |
Alle ansehen
Scpharmaceuticals Inc Aktie (SCPH) Neueste Nachrichten
Corebridge Financial Inc. Raises Holdings in scPharmaceuticals Inc. (NASDAQ:SCPH) - Defense World
Raymond James Financial Inc. Makes New $318,000 Investment in scPharmaceuticals Inc. (NASDAQ:SCPH) - Defense World
U.S. FDA approves ScPharmaceuticals' heart failure therapy - MarketScreener
Market Cool On scPharmaceuticals Inc.'s (NASDAQ:SCPH) Revenues Pushing Shares 30% Lower - simplywall.st
Charles Schwab Investment Management Inc. Acquires 26,964 Shares of scPharmaceuticals Inc. (NASDAQ:SCPH) - Defense World
Bank of New York Mellon Corp Raises Stock Position in scPharmaceuticals Inc. (NASDAQ:SCPH) - Defense World
scPharmaceuticals stock hits 52-week low at $2.73 By Investing.com - Investing.com South Africa
scPharmaceuticals stock hits 52-week low at $2.73 - Investing.com India
Maxim Group Cuts scPharmaceuticals (NASDAQ:SCPH) Price Target to $12.00 - Defense World
scPharmaceuticals Inc. (NASDAQ:SCPH) Q4 2024 Earnings Call Transcript - Insider Monkey
scPharmaceuticals Inc (SCPH) Q4 2024 Earnings Report Preview: Wh - GuruFocus
ScPharmaceuticals outlines FUROSCIX expansion strategy with CKD launch in April 2025 - MSN
Optimistic Buy Rating for scPharmaceuticals Amid Strong Q4 Results and Promising Developments - TipRanks
Analyst Expectations For scPharmaceuticals's Future - Benzinga
Maxim Adjusts Price Target on scPharmaceuticals to $12 From $20, Keeps Buy Rating - Marketscreener.com
scPharmaceuticals Inc (SCPH) Q4 2024 Earnings Call Highlights: Revenue Surge and Strategic ... - Yahoo Finance
scPharmaceuticals Inc (SCPH) Q4 2024 Earnings Call Highlights: R - GuruFocus
scPharmaceuticals Reports Strong Revenue Growth in 2024 - TipRanks
Earnings call transcript: SC Pharmaceuticals Q4 2024 beats EPS forecast By Investing.com - Investing.com Australia
Earnings call transcript: SC Pharmaceuticals Q4 2024 beats EPS forecast - Investing.com
scPharmaceuticals Inc. SEC 10-K Report - TradingView
ScPharmaceuticals, Inc. (SCPH) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
scPharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
scPharmaceuticals Inc (SCPH) Q4 Earnings: EPS Misses, Revenue Be - GuruFocus
SCPHARMACEUTICALS Earnings Results: $SCPH Reports Quarterly Earnings - Nasdaq
scPharmaceuticals Inc. Reports Fourth Quarter and Full Year 2024 Financial Results - TradingView
scPharmaceuticals Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - The Manila Times
Earnings Scheduled For March 19, 2025 - Benzinga
SCPHARMACEUTICALS Earnings Preview: Recent $SCPH Insider Trading, Hedge Fund Activity, and More - Nasdaq
ScPharma Eyes New Frontiers For Furoscix - RTTNews
scPharmaceuticals - The Pharma Letter
scPharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on Wednesday, March 19, 2025 - The Manila Times
scPharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on Wednesday, ... - Post Register
Breakthroughs in Hyperkalemia DrugsMarket Opportunities - openPR
Scpharmaceuticals at Leerink’s Global Healthcare Conference: Strategic Growth Insights By Investing.com - Investing.com Canada
scPharmaceuticals Inc. (NASDAQ:SCPH) Shares Acquired by Rhumbline Advisers - Defense World
scPharmaceuticals (SCPH) to Release Earnings on Wednesday - Armenian Reporter
FDA approves scPharmaceuticals’ Furoscix sNDA for oedema in CKD - Yahoo
H.C. Wainwright maintains Buy on scPharmaceuticals stock, $18 target By Investing.com - Investing.com South Africa
H.C. Wainwright maintains Buy on scPharmaceuticals stock, $18 target - Investing.com India
Strategic Market Expansion and Strong Sales Foundation Drive Buy Rating for scPharmaceuticals - TipRanks
HC Wainwright Cuts Earnings Estimates for scPharmaceuticals - Defense World
FDA nod for scPharmaceuticals’ Furoscix sNDA - The Pharma Letter
ScPharmaceuticals Says US FDA Approves Application to Expand Use of Furoscix -March 06, 2025 at 05:42 pm EST - Marketscreener.com
FDA Approves Expansion for Furosemide Injection to Treat Edema In Patients With CKD - Pharmacy Times
scPharmaceuticals Announces FDA Approval of Supplemental New Drug Application Expanding the FUROSCIX® Indication to Include the Treatment of Edema in Patients with Chronic Kidney Disease - The Manila Times
scPharmaceuticals Announces FDA Approval of Supplemental New Drug Application Expanding the ... - The Bakersfield Californian
FUROSCIX Scores Crucial FDA WinNew CKD Treatment Could Transform Patient Care - StockTitan
SCPH stock touches 52-week low at $3.07 amid market challenges By Investing.com - Investing.com South Africa
SCPH stock touches 52-week low at $3.07 amid market challenges - Investing.com India
FY2029 Earnings Forecast for SCPH Issued By HC Wainwright - Defense World
Finanzdaten der Scpharmaceuticals Inc-Aktie (SCPH)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):